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Abstract
Autophagy pathway has been one of the hot topics during the last decade. From a
general notion about its cellular role, autophagy becomes a more sophisticated
phenomenon with significant implications in cellular homeostasis. Consequently,
autophagy represents an emerging new factor in human diseases. Despite its general
task, the bulk degradation of cellular constituents during starvation settings,
autophagy possesses important cross talk and interrelationships with several cellular
processes such as apoptosis and senescence, among others. This entire panorama
gives us a complex but exciting scenario. Consequently, with the aim of encompassing
the whole spectrum, in this chapter, we review three main topics: autophagy as a
cellular process; autophagy in cell fate; and autophagy in disease. We discuss the
emerging role of selective type of autophagy to avoid apoptosis or necrosis and the
novel relationship between autophagy and senescence to understand the real extent
that autophagy pathway has over cell fate. Finally, we briefly describe the current
trends on autophagy in human pancreatic diseases and its role in cancer cell metab‐
olism.
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1. Introduction
Autophagy is a highly regulated cellular pathway for degrading long-lived proteins and is the
only known pathway for clearing cytoplasmic organelles. Autophagy is a major contributor
to maintain cellular homeostasis and metabolism.
Autophagy is an evolutionarily conserved and highly regulated lysosomal pathway that
degrades macromolecules (e.g., proteins, glycogen, lipids, and nucleotides) and cytoplasmic
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organelles [1-3]. This catabolic process is involved in the turnover of long-lived proteins and
other cellular macromolecules and it might play a protective role in development, aging, cell
death, and defense against intracellular pathogens [4,5]. Moreover, autophagy has been linked
to a variety of pathological processes such as neurodegenerative diseases and tumorigenesis,
which highlights its biological and medical importance [6,7].
Although autophagy was first identified in mammalian liver upon glucagon treatment
approximately 50 years ago, its molecular understanding began only in the past decade, largely
based on the discovery of the autophagy-related genes (ATGs) by genetic analyses in yeast.
Since the discovery of the yeast ATG proteins, autophagosome formation has been dissected
at the molecular level, but a lot of questions about this pathway remain unanswered. In
mammalian cells, the sequential association of at least a subset of the ATG proteins leads to
the assembly of the pre-autophagosome structure (PAS). PAS formation also requires PtdIns3P
generation and it is thought that this lipid is present in specialized subdomains of membranes
where the PAS is assembled and autophagosomes are generated.
One of the autophagy-related proteins is VACUOLE MEMBRANE PROTEIN 1 (VMP1), whose
expression triggers autophagy in mammalian cells even under nutrient-rich conditions.
Conversely, autophagy is completely blocked in the absence of VMP1. VMP1 is required for
the biogenesis of autophagosomes in mammalian cells in all conditions underscoring its
upstream regulatory function in autophagy. Importantly, VMP1 is also expressed early during
the onset of several pathologies including diabetes mellitus, pancreatitis, and pancreatic
cancer.
The presence of autophagy has been described in dying acinar cells in tissue from human
diseases. Though controversy exists about whether autophagy could be at the same time a
survival cell response and a programmed cell death pathway, there is no discussion that
autophagy has the power to change the fate of a cell. From an energetic homeostasis point of
view, autophagy is a major cellular response against starvation condition and plays key roles
in other cellular stress conditions such as oxidative damage. In those cases, autophagy is not
only a way to keep energy and nutrition but also a specific mechanism of cell adaptive
response.
Increasing evidence suggests that autophagy may influence the pathogenesis of human
diseases including cancer, neurodegenerative diseases, inflammatory diseases, and metabolic
diseases. Several inherited myopathies are associated with aberrant autophagy. Recent
investigations have explored the functions of autophagy in the pathogenesis of metabolic
disorders such as diabetes, insulin resistance, and obesity, and the progression of aging.
It is possible to think that different types of autophagy may be involved in the initial cellular
events induced by the noxa. Autophagic processes might be triggered in different cells by
several diseases and probably they are more complex than we actually understand. These
pathways function as adaptive responses that mostly act as protective mechanisms against cell
healing. The knowledge of the molecular mechanisms of a sophisticated membrane transport
system such as autophagy would provide bases for novel and more rational diagnostic and
therapeutic strategies.
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2. Autophagy, a complex cell event
Autophagy consists of several sequential steps: induction, autophagosome formation,
autophagosome-lysosome fusion, and degradation. Depending on the delivery route of the
cytoplasmic material to the lysosome, there are three major types of autophagy in eukaryotes:
1) chaperone-mediated autophagy (CMA), 2) microautophagy, and 3) macroautophagy,
hereafter referred to as autophagy [8]. CMA allows the direct lysosomal import of unfolded
soluble proteins that contain a particular pentapeptide motif. In microautophagy, cytoplasmic
material is directly engulfed into the lysosome at the surface of the lysosome by membrane
rearrangement. Finally, autophagy involves the sequestration of cytoplasm into a double-
membrane cytosolic vesicle referred to as an autophagosome that subsequently fuses with a
lysosome to form an autolysosome for degradation by lysosomal hydrolases [9].
2.1. The autophagic process
Autophagy is characterized by sequestration of bulk cytoplasm and organelles in double-
membrane vesicles called autophagosomes that eventually acquire lysosomal-like features
[9,10]. The autophagic process is described in Figure 1.
Figure 1. General scheme of autophagic process. During autophagy an isolation membrane forms, invaginates and se‐
questers cytoplasmic constituents. The edges of the membrane fuse to form the autophagosome. The outer membrane
of the autophagosome fuses with the lysosome to form the autolysosome, where the cargo is degraded.
Briefly, sequestration of cytoplasm into a double-membrane cytosolic vesicle is followed by
the fusion of the vesicle with a late endosome or lysosome to form an autophagolysosome (or
autolysosome). Then, inner membrane of the autophagosome and autophagosome-containing
cytoplasm-derived materials are degraded by lysosomal/vacuolar hydrolases inside the
autophagosome. The molecular mechanisms underlying the transport and fusion of autopha‐
gosomes are just beginning to be understood and through active investigations, several major
events involved in the process have recently been clarified including the recycling of lysosomes
[11]. In mammalian cells, autophagosome maturation is a prior step for the fusion between
autophagosomes and lysosomes. The degradation products, including macromolecules, are
then exported to the cytosol for reuse by the cell.
2.2. The autophagosome at a molecular level
Since the discovery of yeast ATG proteins, autophagosome formation has been dissected at
the molecular level but a lot of questions about the molecular mechanism underlying this
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process remain unanswered. Autophagosomes can be considered unique organelles because
they do not contain marker proteins of other subcellular compartments [12]. In mammalian
cells, the sequential association of at least a subset of the ATG proteins leads to the assembly
of the PAS that is believed to be the site where the precursor structure of the autophagosomes,
the phagophores, are generated [13]. The PAS and phagophore formation also requires
phosphatidylinositol 3-phosphate (PI3P) [14] and it is believed to be associated to specific
subdomains of the endoplasmic reticulum (ER), termed omegasomes [15,16]. Among the key
mediators initiating autophagosome formation, there is a set of evolutionarily conserved ATG
gene products: the kinase-containing Ulk1/2 complex (ATG1 in yeast), the Class III phospha‐
tidylinositol 3-kinase (PI3K) complex (composed by BECN1/ATG6-hVps34, hVps15 and
ATG14L), the ubiquitin-like conjugation systems leading to the formation of the ATG5–
ATG12–ATG16L1 complex, and the LC3/ATG8 phosphatidylethanolamine-conjugate (e.g.,
LC3-II) [17]. A second group of ATG proteins, which does not have orthologous group in yeast,
has also recently emerged and appears to play a key role in regulating autophagy in high
eukaryotes. One of these proteins is the transmembrane protein VMP1, whose expression
triggers autophagy in mammalian cells even under nutrient-rich conditions [18,19]. Converse‐
ly, autophagy is completely blocked in the absence of VMP1 [18].
The autophagosome formation process is composed of isolation membrane nucleation,
elongation, and completion steps. In mammals, the Class III PI3K plays an essential role in
isolation membrane nucleation during autophagy [20]. The Class III PI3K is associated with
BECN1/ATG6 and p150, the homolog of Vps15 (phosphoinositide-3- kinase regulatory subunit
4), to form the PI3K complex. This kinase catalyzes the generation of PI3P on the autophago‐
somal membrane, favoring the localization of other ATG proteins to the PAS during autopha‐
gosomal formation. The autophagosome nucleation system is ATG12-ATG5-ATG16L, which
is a ubiquitin-like protein conjugation system essential for the formation of the PAS. ATG12
is conjugated to ATG5 [21]. E1-like ATG7 activates the carboxyl-terminal glycine residue of
ATG12 through a high-energy thioester bond in an ATP-dependent manner. The ATG12-ATG5
conjugate further interacts with ATG16L1 to form a ~350 kDa multimeric ATG12-ATG5-
ATG16L protein complex through the homo-oligomerization of ATG16L [22]. Another
ubiquitin-like protein conjugation system is the modification of LC3 (a mammalian homolog
of ATG8) by the phospholipid phosphatidylethanolamine (PE) [22], an essential process for
the formation of autophagosomes. The cytosolic form of LC3 (LC3-I) is cleaved by cysteine
protease ATG4 and then conjugated with PE by ATG7 and ATG3. This lipidated LC3 (LC3-II)
then associates with newly forming autophagosome membranes. LC3-II remains on mature
autophagosomes until its fusion with lysosomes [23, 24]. The conversion of LC3-I to LC3-II is
thus well known as a marker of autophagy (Figure 2). However, the increase of LC3-II alone
is not enough to show autophagy activation because the inhibition of LC3-II degradation in
the lysosome by the impaired autophagy flux can also cause its accumulation.
While the origin of autophagic vacuoles remains disputable, several hypotheses have been
proposed for the source of autophagosomal membrane during autophagosome formation. The
first hypothesis is “de novo” formation of autophagosome by ATG9 reservoirs. In the second
hypothesis, various organelles such as ER, mitochondria, and plasma membrane are used as
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an origin for the formation of the phagophore. Recently, cup-shaped structures called ome‐
gasome, a discrete region of the ER, were identified as a platform for autophagosome formation
[25]. The ATG5 complex, LC3, and ULK1 have been shown to recruit into the omegasome after
starvation, and ATG5- and LC3-positive membranes seem to emerge from the omegasome. It
was also observed that omegasomes form in close proximity to the PI3K-containing vesicles
which may synthesize the PI3P. This hypothesis is also supported by a notion of a physical
association between the ER and early autophagic membranes [26].
2.3. Autophagy induction
Basal autophagy in unstressed cells is kept down by the action of the mammalian target of
rapamycin complex 1 (mTORC1). Key upstream regulators of mTORC1 include the class I
phosphoinositide 3-kinase-Akt pathway which keeps mTORC1 active in cells with sufficient
growth factors and the AMP-activated protein kinase (AMPK) pathway that inhibits mTORC1
upon starvation and calcium signals [27,28].
Under stress conditions such as amino acid starvation, autophagy is strongly induced in many
types of cultured cells. The effects of individual amino acids differ in their abilities to regulate
autophagy. Amino acids including Leu, Tyr, Phe, Gln, Pro, His, Trp, Met, and Ala suppress
autophagy in ex vivo perfused liver [29]. However, such profiles depend on cell types showing
their different amino acid metabolisms in tissues. The questions on how cells sense amino acid
concentration and physiological significance of autophagy regulation by amino acid starvation
are not fully understood yet. It has been demonstrated that amino acid signaling pathways
exist, which involve activation of mTORC1 and the subsequent regulation of the Class III PI3K.
mTORC1 is involved in the control of multiple cell processes in response to changes in nutrient
conditions [30]. Especially, mTORC1 requires Rag GTPase, Rheb, and Vps34 for its activation
and subsequent inhibition of autophagy in response to amino acids [31, 32]. Energy levels are
primarily sensed by AMPK, a key factor for cellular energy homeostasis. In low energy states,
AMPK is activated and the activated AMPK then inactivates mTORC1 through TSC1/TSC2
and Rheb protein [33].
Thus, inactivation of mTORC1 is essential for the induction of autophagy and plays a central
role in autophagy. In addition to amino acid signaling, hormones, growth factors, and many
other factors including Bcl-2 [34] have also been reported to regulate autophagy. But, not all
autophagy signals are transduced through mTOR signaling. A recent study showed that small-
Figure 2. During autophagy the cytosolic form of LC3 (LC3-I) undergoes C-terminal proteolysis and lipidation (LC3-II)
and translocates to the autophagosomal membrane. LC3 is currently used as a specific marker of autophagy.
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molecule enhancers of the cytostatic effects of rapamycin (called SMERs) induce autophagy
independently of mTOR [35]. Activities of the ULK1 are regulated by mTOR depending on
nutrient conditions. Under growing and high-nutrient conditions, active mTORC1 interacts
with ULK1 and phosphorylates ULK1 and mATG13 and, thus, inhibits the membrane
targeting of the ULK1. During starvation condition, on the other hand, inactivated mTORC1
dissociates from ULK1 and results in the ULK1 complex formation (ULK1-mATG13-FIP200-
ATG101) leading to autophagy induction [36].
2.4. The autophagy-related protein Beclin 1 (BECN1)
BECN1 (former Beclin 1), the mammalian ATG6, is a haploinsufficient tumor suppressor and
an important effector of autophagy. BECN1 is a subunit of the PI3K complex, the action of
which is antagonized by Bcl-2 [36,37]. BECN1 contains a BH3 domain that mediates its
interaction with Bcl-2 [38,39]. The interaction between Bcl-2 and BECN1 leads to inhibition of
autophagy by interfering with the formation and activity of the autophagy promoter complex,
BECN1- PI3K [40] (Figure 3).
Figure 3. BECN1 is an effector of autophagy whose interaction with Bcl-2 inhibits its role as autophagy promoter.
BECN1 and the PI3K complex, where hVP34 is the active subunit, are necessary for PI3P production over the autopha‐
gic structures and the consequent recruitment of additional ATG proteins.
2.5. The Vacuole Membrane Protein 1 (VMP1)
The pancreatitis-associated protein named VMP1 is a transmembrane protein with no known
homologs in yeast. VMP1 was found searching for new molecules that were differentially
expressed during acute pancreatitis [41]. VMP1 expression is induced by mutated K-Ras in
pancreatic cancer cells [42] and by hyperstimulation of Gq-coupled cholecystokinin receptor
(CCK-R) in pancreatic acinar cells during acute pancreatitis [43]. In the adult normal pancreas,
VMP1 expression is not detectable but it is highly induced early during experimental acute
pancreatitis and its expression levels correlate with morphological features resembling
autophagy [44]. Moreover, VMP1 expression can be found in pancreatic acinar cells from rats
developing spontaneous chronic pancreatitis (WBN/Kob rats) [45] and it is rapidly and highly
expressed in experimental diabetes [45-47]. Finally, gemcitabine (2,2-difluorodeoxycytidine),
the standard chemotherapy for the treatment of advanced pancreatic cancer, induces VMP1
expression in human pancreatic cancer cells [48-50]. We demonstrated that VMP1 expression
triggers autophagosome formation in mammalian cells even under nutrient-replete conditions
[18,19]. Remarkably, VMP1 pancreas-specific transgenic expression in mice promotes auto‐
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phagosome formation in acinar cells. Therefore, VMP1 expression may be involved in
autophagy induction during acute pancreatitis, a disease defined as pancreas self-digestion.
Furthermore, VMP1 is the only human-disease-inducible ATG-protein described so far.
VMP1 interacts with BECN1 through its hydrophilic C-terminal region (VMP1-ATGD) that is
necessary for early steps of autophagosome formation. Hierarchical analyses in mammalian
cells shows that VMP1 along with ULK1 localizes in the autophagosome formation site [13].
VMP1-BECN1 interaction is required for the formation of the PI3K complex acting in mam‐
malian autophagy. This complex, which is composed of BECN1-hVps34-ATG14, promotes
PI3P generation on autophagosomal membrane, favoring the localization of ATG16L1 and
LC3 to the autophagosomal membrane during autophagosome formation [51,52]. The
interaction between VMP1 and BECN1 requires the BECN1 domain that binds to Bcl-2
(BECN1-BH3 domain) [51]. During normal growth conditions, Bcl-2 binding to BECN1 is
maximal, and when autophagy is induced, this interaction is strongly reduced [53]. VMP1
expression leads to the dissolution of the BECN1-Bcl-2 complex, indicating that VMP1 is
involved in driving BECN1 into the autophagic process [38]. Thus, VMP1-BECN1 interaction
through the VMP1-ATGD is required for the proper localization of PI3K activity on the
autophagosomal membrane during mammalian autophagy, positioning VMP1 as a key
regulator of the early steps of autophagosome formation possibly acting as a platform in the
autophagosomal membrane.
2.6. Autophagy, a selective process
Early studies suggested that autophagy was a nonselective process in which cytoplasmic
structures were randomly sequestered into autophagosomes before being delivered to the
mammalian lysosome or the plant and yeast vacuole for degradation. Now, there is growing
evidence that unwanted cellular structures can be selectively recognized and exclusively
eliminated within cells. This is achieved through the action of specific autophagy receptors
such as Nbr1 and p62, which is a ubiquitin-binding protein that interacts with LC3 [10,54].
Thus, excess or damaged organelles, including mitochondria, peroxisomes, lipid droplets,
endoplasmic reticulum, and ribosomes, can be specifically sequestered by autophagosomes
and targeted to the lysosome for degradation. Importantly, there is growing evidence that
selective autophagy subtypes also have a wide range of physiological functions. Selective
autophagic pathways target distinct cargoes to autophagosomes including mechanisms for
the clearance of aggregated protein and for the removal of dysfunctional mitochondria
(mitophagy). In pancreatic cells, autophagy has recently been shown to specifically turn over
secretory granules damaged by acute pancreatitis as a protective cellular response [43].
2.7. Zymophagy, a novel selective type of autophagy
The pancreatic acinar cell activates VMP1-mediated autophagy early during acute pancreatitis
[44]. Relevant data about the role of autophagy in pancreas were obtained using ElaI-VMP1
mice in which the pancreaatic acinar-cell-specific elastase promoter drives VMP1 expression
in pancreas. Pancreases of these transgenic mice show numerous vesicles that stain for
endogenous LC3, indicating that VMP1 induces the autophagosome formation and, therefore,
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autophagy [18]. Interestingly, ElaI-VMP1 mice do not develop pancreatitis in normal condi‐
tions, confirming that autophagosome formation does not induce acute pancreatitis [18]. The
immunomagnetic isolation of VMP1-autophagosomes containing zymogen granules from the
ElaI-VMP1 transgenic mouse pancreas with acute pancreatitis allowed the discovery of a new
type of selective autophagy named zymophagy that functions as an inducible cellular process
that recognizes and degrades activated zymogen granules [43].
Zymophagy is characterized by the formation of autophagosomes containing zymogen
granules. These organelles mediate the sequestration and degradation of pancreatitis-activated
zymogen granules. CCK-R hyperstimulation with cerulein in wild-type animals, a classical
model of acute pancreatitis, induced a markedly altered distribution pattern of the secretory
granules such as fusion among zymogen granules as well as their fusion with condensing
vacuoles. In addition, acinar cells lose their polarity, which results in the relocation of zymogen
granules to the basolateral membrane. Surprisingly, ElaI-VMP1 mice subjected to CCK-R
hyperstimulation reveal that acinar cells preserve their structure and polarity with negligible
or no alteration in vesicular transport. Instead, pancreases from cerulein-treated ElaI-VMP1
mice presented autophagosomes containing zymogen granules displaying a distinct localiza‐
tion to the apical area of the acinar cell. This observation is confirmed using isolated mouse
pancreas acini revealing that 15 min after cerulein treatment, zymophagy is detected [43]. The
finding of different maturation levels of selective autophagic vesicles as well as the degradation
of p62 provide evidence that autophagic flow remains primarily unchanged under CCK-R
hyperstimulation [43].
Regarding the pathophysiological relevance of zymophagy during acute pancreatitis, it was
demonstrated that zymophagy protects acinar cells from intracellular trypsinogen activation
triggered in vivo by experimental pancreatitis induced by cerulein. Upon CCK-R hypersti‐
mulation, wild-type mice developed acute pancreatitis with high amylase and lipase serum
levels. On the contrary, enzymatic levels in cerulein-treated ElaI-VMP1 mice were significantly
lower compared with wild-type mice. Consistently, ElaI-VMP1 mouse pancreas showed
remarkably less macroscopic evidence of acute pancreatitis compared with wild-type animals
that showed marked edema and hemorrhage. Histological analyses displayed a high degree
of necrosis as well as inflammation in wild-type pancreas with acute pancreatitis. In contrast,
neither necrosis nor significant inflammation was seen in cerulein-treated ElaI-VMP1 mice
[41,43]. Thus, results obtained in the transgenic animal model showed that zymophagy
functions as a protective pathophysiological mechanism against pancreatitis-associated injury.
Upon CCK-R hyperstimulation, acinar cells from wild-type mice showed early cytoplasmic
trypsinogen activation, which is a hallmark of pancreatitis pathophysiology. Surprisingly, in
acinar cells from ElaI-VMP1 mice, CCK hyperstimulation caused almost no activation of
trypsinogen. Microscopic examinations using BZiPAR (rhodamine 110 bis-[CBZ-L-isoleucyl-
L-prolyl-L-arginine amide] dihydrochloride), a cell permeable substrate that becomes fluo‐
rescent after the cleavage by the protease revealed only few activated granules that highly
colocalize with VMP1, showing that zymophagy selectively sequesters the activated zymogen
granules. Zymogen activation is an enzymatic chain reaction where initial zymogen granule
alterations trigger rapid spread of active trypsin within the acinar cell. We think that the
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degradation of early-activated zymogen granules by zymophagy prevents this deleterious
event. Interestingly, the inhibition of autophagic flow markedly increased trypsin activity
within acinar cells in ElaI-VMP1 mouse pancreases under CCK-R hyperstimulation confirming
that zymophagy specifically degrades those zymogen granules that are initially activated by
acute pancreatitis [43]. This function is confirmed in the in vivo animal model of acute
pancreatitis where the ability of the ElaI-VMP1 mouse developing zymophagy clearly prevents
the increment of enzymatic markers of pancreatic damage and morphological changes
characteristic of acute pancreatitis.
Analysis of autophagosomes containing zymogen granules magnetically immunopurified
from the pancreas of ElaI-VMP1 mice treated with cerulein revealed that, apart from zymogen
granules, isolated vesicles contained LC3-II and, notably, strong signals of p62. Moreover,
GFP-ubiquitin-transfected acinar cells subjected to CCK-R hyperstimulation showed colocal‐
ization between activated granules and ubiquitin aggregates but do not show colocalization
between unaffected or normal zymogen granules and ubiquitin, indicating that the ubiquitin
system serves as a targeting signal for activated zymogen granules during zymophagy.
Therefore, activated zymogen granules are directly or indirectly ubiquitinated for their
recognition by autophagic membranes in which ubiquitin acts as a label for selective engulf‐
ment. Nevertheless, activated zymogen granules were ubiquitinated upon acute pancreatitis
and the VMP1-mediated selective autophagic pathway sequestered these ubiquitinated
granules [43]. p62 may function as a cargo receptor during zymophagy. These data demon‐
strate for the first time that ubiquitin modifications may possess an additional function in
acinar cells by promoting the degradation of highly harmful activated zymogen granules [55].
Zymophagy prevents pancreatic acinar cell death induced by CCK-R hyperstimulation [43].
Autophagosome formation inhibition with 3-methyladenine as well as autophagy flux
interruption with vinblastine significantly reduced acinar cell survival in a cell model of acute
pancreatitis. Moreover, VMP1 downregulation (shVMP1) also significantly decreases acinar
cell survival under CCK-R hyperstimulation, showing that VMP1 expression and autophagy
is required to prevent acinar cell death in acute pancreatitis. Therefore, VMP1 expression is
activated in acinar cells to mediate zymophagy as a protective cellular response against cell
death [55].
Furthermore, VMP1 expression and zymophagy are present in human pancreas affected by
acute pancreatitis [43,55]. VMP1 is not detectable in human normal pancreas tissue but its
expression is activated in human pancreatitis pancreatic specimens and highly colocalized
with LC3 in autophagosomes. Moreover, autophagosomes markedly colocalized with
zymogen granules. Remarkably, the finding of large autolysosomes without trypsin signal in
pancreas of human pancreatitis suggests that affected zymogen granules are eventually
degraded by zymophagy during human pancreatitis.
3. Autophagy in cell fate
Though there was controversy about whether autophagy could be at the same time a survival
cell response and a programmed cell death pathway, there is none that autophagy has the
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power to change the fate of a cell. From an energetic homeostasis point of view, autophagy is
a major cellular response against starvation condition. Nevertheless, we have to keep in mind
that autophagy plays key roles also in other cellular stress conditions such as oxidative damage
[57,58], damaged organelles elimination [59-61], depletion of toxic proteins aggregates [62],
host response to microorganisms [61], etc. In those cases, autophagy is not just a way to keep
energy and cellular material but a specific cellular stress response. Therefore, it is not difficult
to imagine that autophagy could be observed in several cellular life-threatening situations and,
then, its pro-survival or pro-death role becomes diffuse. Solid and ineligible is the fact that,
independently, its situation-specific role, a determined autophagy process, has a profound
impact in the cellular fate.
3.1. Autophagy as nutritional stress response
We must begin our analysis from the most basic and evolutionarily conserved autophagy duty
as nutrient stress response. In the starvation context, autophagy plays the first explored, and
may be more obvious, task of autophagy, that is, the energy cellular support during nutrient-
limiting conditions. Though the bulk degradation and recycling of cytoplasmic portions seem
to be a simple event in cellular life, it has major consequences in cell fate and organismal
adaptation. As it could be imagined, a proper autophagic flux during a challenging cellular
nutritional status might be determinant for the cell survival. Furthermore, the importance of
starvation-induced autophagy for cell survival can have beneficial or detrimental consequen‐
ces to tissue in context dependence. For instance, autophagy could give a life opportunity to
cells under urgent energy requirement such as organ starvation, ischemia, hypoxia, etc., being
beneficial for a determinate tissue. On the other hand, the same mechanism gives to pancreatic
cancer cells enough adaptation to survive in a highly hipoperfunded environment of the
pancreatic tumor [63]. This dual behavior could also be observed with AMPK (5' AMP-
activated protein kinase) which is one of the master regulators of the cellular energetic
homeostasis and a direct autophagy trigger through ULK1 phosphorylation [64]. Similar to
what is observed with autophagy, AMPK could be a tumor suppressor, stopping all anabolic
process and activating all the catabolic ones including autophagy (probably contributing to
the oncogene-induced senescence – see below) but, in other circumstance, it gives tumor high
resistance to stress [65].
3.2. Autophagy and cell death
Connections between autophagy and disease have attracted an increasing amount of attention.
By morphological studies, autophagy has been linked to a variety of pathological processes
and autophagy was associated with cell death. Taking cell death as one major topic in cell fate,
there are a large amount of data concerning the complex relationship between autophagy and
apoptosis [65,66]. However, this relationship is far from being fully understood and, in many
cases, it seems to be context-dependent. This autophagy–apoptosis relationship could be
observed from the beginning since they share several inducing factors such as ROS [57],
increased levels of cytosolic calcium concentrations [67], oncogenes, and p53 [68], among
others (Figure 4A). Among those, the BH3-only proteins have a prominent role. These are pro-
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apoptotic and different from the Bcl-2 family proteins which contain only one BH3 (Bcl-2
homology 3) domain [69]. BECN1 is a fundamental protein in autophagic mechanism (as
mentioned above). This protein was one of the first described mammalian autophagy-related
proteins [70]. BECN1 interacts with proteins of Bcl-2 family (Bcl-2, Bcl-XL and Mcl-1) [71].
Through interaction with the BECN1 BH3 domain, these proteins are able to inhibit BECN1-
mediated autophagy [72, 73]. What is more, this interaction makes BECN1 not only a highly
relevant autophagy actor but it is indeed also a haploinsufficient tumor suppressor [74]. On
the other hand, BH3-only proteins are capable of disruption of Bcl-2-BECN1 interaction
inducing apoptosis by Bcl-2 blockade and autophagy by releasing BECN1 [75].
Experimentally, impairment of autophagy in starving cells is able to induce apoptosis or at
least a kind of cell death. This autophagy shortage impedes cell proper management of a
metabolic stress or, in some cases, such as neurons, clearance of toxic cellular metabolic
products. Moreover, in some way, this effect seems to be in both sides since inhibition of
apoptosis could also be a potent trigger of the autophagy process. Transgenic depletion of pro-
apoptotic molecules such as Bax or Bak or the use in vitro of the pan-caspase inhibitor Z-VAD-
FMK were able to strongly induce autophagy and a cell death which is inhibited by autophagy
inhibitors [76,77]. This seems to be the rule in most cases, a highly intricate autophagy-apotosis
cross talk, where, despite their respective main duties, they act by inhibiting each other (Figure
4A). For instance, in one way, autophagy could reduce the cytosolic concentrations of pro-
apoptotic proteins [78]. In the other way, activated caspases are able to cleave some autophagic
proteins in which the fragmented products indeed acquired now pro-apoptotic properties
[79-83]. Such is the case of ATG5, BECN1, and ATG4D [79-83].
Beyond the central role of ATG5 in autophagy machinery, this protein, in some situations, is
able to induce apoptosis by two different ways. As mentioned above, a calpain-mediated
cleaved ATG5 translocated to mitochondria, favoring its depolarization and triggering of
apoptosis [84]. Moreover, ATG5 can also associate to FADD (Fas-associated death domain)
enhancing apoptosis cell death [85].
The autophagic cell death is a programmed alternative to other sorts of cell demise. All of the
comments above about the relationship of autophagy with cell death do not imply that
autophagy could be by itself a cell death mechanism. Many researchers have suggested a
number of times the existence of a really programmed autophagic cell death. Nevertheless,
since autophagy is a cell survival pathway, there was concern about whether autophagy was
a last cellular attempt to avoid apoptosis or if autophagy-related cell death only occurs in in
vitro settings. These controversies were clarified with study of the degeneration of salivary
glands during the D. melanogaster embryogenesis [86]. These glands suffered a cell death that
is independent of caspases and completely dependent on autophagy [87].
All this intricate cross talk among apoptosis, autophagy, and autophagic cell death makes one
rethink the definition of cell death types. Hence, the 2015 Nomenclature Committee on Cell
Death made a switch from morphological- to biochemical-based definitions of cell death types
[87]. They stated that autophagic cell death will be defined as processes of cell death that were
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prevented by the use of pharmacological or genetic tools targeting at least two different
components of autophagy machinery [87].
Beyond the molecular mechanism, autophagy is able to modulate the cell death response and,
hence, cell fate indirectly. Mitophagy, the most studied form of selective autophagy, is aimed
to eliminate damaged mitochondria contributing to its renewing and ROS homeostasis [88].
As mitochondrial impairment is one of most important apoptosis triggering events, elimina‐
tion of damaged mitochondria could avoid the intrinsic apoptosis program (Figure 4B).
Damaged mitochondria and subsequent decrease in the inner mitochondrial transmembrane
potential (Δ Ψ) led to leakage of several harmful substances such as ROS and intrinsic
apoptotic-pathway-triggered leakage of others such as cytochrome c [88]. In response,
damaged mitochondria may be fragmented and ubiquitinated by a PINK-Parkin-dependent
mechanism [89]. Then, these damaged organelles are recognized and selectively eliminated
by autophagy in order to allow the cell survival [64,83].
It is surprising that autophagy can also interfere with such an uncontrolled process as necrosis.
This example was demonstrated to occur during acute pancreatitis with zymophagy [55]. In
the cellular basis of this disease, there was a premature intracytoplasmic activation of digestive
enzymes [41]. This last activity pushes pancreatic acinar cell to an inevitable necrosis and the
catastrophe of the tissue in a sort of chain cascade [41]. Zymophagy, as selective type of
autophagy, eliminates the granules where the dangerous zymogens were activated by a
ubiquitin recognition mechanism [55]. This protective mechanism avoids the enzymatic
autodegradation and subsequent necrosis of the acinar cell [55] (Figure 4B). This event, in fact,
has consequences beyond cellular biology since it reduces gland inflammation and contributes
to autolimitation of the disease.
3.3. Autophagy and cellular senescence
There exists another unexpected process related to cell fate which is influenced by autophagy:
the cellular senescence [90]. This term is used to describe an irreversible (which differentiates
it from quiescence) deep arrested status of the cell cycle. The senescence is a cellular alternative
mechanism to apoptosis in response to certain stressors including oncogene overexpression.
Then, the so-called oncogene-induced senescence is a potent tumor suppressor mechanism
against cellular transformation [91-94] and it is the first option that cells have against oncogene
activation. Autophagy participated in the transition phase of senescence establishment being
part of the TOR-autophagy spatial coupling compartment (TASCC). The TASCC is a cyto‐
plasmic sub-compartmentalization where mTOR is closely associated with lysosomes/
autolysosomes fuelled by a constant autophagy flow outside of this area [95]. This activity
resulted in an efficient synthesis-degradation coupling that seems to be crucial for senescence.
Inhibition of autophagy impairs the senescent progression and it seems to be necessary to reach
an intermediate state before the final setting of senescent phenotype. Finally, it was suggested
that autophagy during senescence is triggered by the isoform ULK3 instead of ULK1 or ULK2;
therefore, it is tempted to hypothethize that a specific type of autophagy may be related to
senescence (Figure 4B).
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Figure 4. The implication of autophagy in cell fate. A) There is a deep crosstalk between autophagy and apoptosis.
They share several common inducers and posses regulatory properties on each other. B) Autophagy is able to modify
cell fate and some examples are depicted. Mitophagy eliminates the damaged mitochondria avoiding the apoptosis
triggered by intrinsic pathway (upper panel). By the specific elimination of activated zymogen granules, zymophagy
prevents the acinar cell damage and the necrosis in pancreas tissue (middle panel). Autophagy participates in the on‐
cogene-induced senescence, a process capable of repress the oncogenic transformation (lower panel).
4. Autophagy in pancreatic diseases
Pathological processes such as pancreatitis and diabetes mellitus as well as cancer cell
transformation and also cancer chemotherapy activate autophagy in human tissues and
human tumor cells. While human normal pancreatic acinar cells do not have detectable
autophagy levels, pancreatic diseases activate autophagy, confirming the relevant role of
autophagy in human pancreatic disease. In addition, selective autophagy of pancreatic
zymogen granules, zymophagy, has been discovered and characterized as a cell-protective
process activated by the disease.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies
with 2-3% five-year survival rate. It remains a devastating and poorly understood malignancy.
Its poor prognosis has been attributed to the inability to make a diagnosis while the tumor is
still resectable and a propensity toward early vascular dissemination and spread to regional
lymph nodes. Up to 60% of patients have advanced pancreatic cancer at the time of diagnosis
and their median survival time is a dismal 36 months. This is due to both the aggressive nature
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of the disease, the lack of specific symptoms and early detection tools, and its relatively
refractory response to traditional cytotoxic agents and radiotherapy. Moreover, pancreatic
cancer cells become more malignant or survive with an extremely poor blood supply. So far,
little and contradictory data are available regarding the activity of autophagy and its regulation
in pancreatic cancer cells. Experimental evidence pointed at autophagy as a pancreatic cancer
cell mechanism to survive under adverse environmental conditions or as a defective program‐
med cell death mechanism that favors pancreatic cancer cell resistance to treatment.
4.1. Autophagy in cancer cell
Both downregulated and excessive autophagy have been implicated in the pathogenesis of
diverse diseases such as certain type of neuronal degeneration, diabetes and its complications,
and cancer [96]. Autophagy has also been implicated in cell death called autophagic or type II
programmed cell death, which was originally described on the basis of morphological studies
detecting autophagic vesicles during tissue involution [97].
Cancer cells in general tend to undergo less autophagy than their normal counterparts at least
for some tumors [98,99]. The BECN1 autophagy gene is monoallelically deleted in 40-74% of
cases of human sporadic breast, ovarian, and prostate cancer [99]. Heterozygous disruption of
BECN1 increases the frequency of spontaneous malignancies and accelerates the development
of virus-induced premalignant lesions [99] suggesting that defective regulation of autophagy
promotes tumorigenesis. It has been proposed that autophagy suppresses carcinogenesis by
a cell-autonomous mechanism involving protection of genome integrity and stability, and a
nonautonomous mechanism involving suppression of inflammation and necrosis. On the
other hand, autophagy may support the survival of rapidly growing cancer cells that have
outgrown their vascular supply and are exposed to an inadequate oxygen supply or metabolic
stress. By contrast, excessive levels of autophagy promote cell death [100]. Accordingly, it has
been proposed that autophagy plays an important role both in tumor progression and in
promotion of cancer cell death [101], although themolecular mechanisms responsible for this
dual action of autophagy in cancer have not been elucidated.
It has been suggested that autophagy may be a cancer cell survival response to tumor-
associated hypoxia. Tumor hypoxia has been used as a marker of poor prognosis [102];
however, how cancer cells become more malignant or survive with an extremely poor blood
supply is poorly understood. When cancer cells are exposed to hypoxia, anaerobic glycolysis
increases and provides energy for cell survival but as the glucose supply is also insufficient
because of the poor blood supply, there must be an alternative metabolic pathway that
provides energy when both oxygen and glucose are depleted [103,104]. Hypoxia in pancreatic
cancer has been reported to increase its malignant potential [102]. Proliferating cancer cells
require more nutrients than surrounding noncancerous cells do, though nutrition is supplied
via functionally and structurally immature neovessels. Because autophagy-specific genes
promote the survival of normal cells during nutrient starvation in all eukaryotic organisms,
autophagy may react to the cancer microenvironment to favor the survival of rapidly growing
cancer cells. LC3 expression in surgically resected pancreatic cancer tissue showed activated
autophagy in the peripheral area, which included the invasive border, and concomitantly
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shows enhanced expression of carbonic anhydrase [105]. This observation suggests that
autophagy may promote cell viability in hypovascularized cancer tissue.
It has also been proposed that autophagy is a cancer cell survival response to tumor-associated
inflammation [106]. Cancer-associated inflammation results in promotion of carcinogenesis
and resistance to therapy. Several phenotypic alterations observed in cancer cells are a result
of inflammatory signals found within the tumor microenvironment [106]. The receptor for
advanced glycation end products (RAGE) is an induced inflammatory receptor constitutively
expressed on many murine and human epithelial tumor cell lines [107,108] and the highest
levels of RAGE expression were observed in murine and human pancreatic adenocarcinoma
tumors. Genotoxic and/or metabolic stress lead to modest but reproducible increases in overall
expression of RAGE on epithelial cell lines. RAGE expression correlates directly with the ability
of both murine and human pancreatic tumor cell lines to survive cytotoxic insult. Targeted
knockdown of RAGE significantly increased cell death, whereas forced overexpression
promotes survival. Recently, it was reported that the enhanced sensitivity to cell death in the
setting of RAGE knockdown is associated with increased apoptosis and decreased autophagy.
In contrast, overexpression of RAGE is associated with enhanced autophagy, diminished
apoptosis, and enhanced cancer cell viability. Knockdown of RAGE enhances mTOR phos‐
phorylation in response to chemotherapy, thus preventing induction of a survival response.
Inhibition of autophagy by means of silencing BECN1 expression in pancreatic cancer cells
enhanced apoptosis and cell death [109]. These observations suggest that RAGE expression in
cancer cells has a role in tumor cell response to environmental stress through the enhancement
of autophagy. However, increased sensitivity to chemotherapeutic agents in RAGE-knock‐
down pancreatic cancer cells is dependent on ATG5 expression but independent of BECN1
expression [109]. These last findings suggested that the role of autophagy in the resistance to
microenvironment insult or in the sensitivity to chemotherapeutic agent is the result of
complex molecular pathways in the tumor cell.
On the other hand, repression of autophagy has been suggested as a cancer cell response
to prolonged hypoxic conditions. Pancreatic cancer cell response to prolonged hypoxia may
consist of inhibition of autophagic cell death. The short isoform of single-minded 2 (SIM2s)
is a member of the basic helix-loop-helix family of transcriptional regulators [110] and is
upregulated  in  pancreatic  cancer.  Microarray  studies  identified  the  pro-cell  death  gene
BNIP3  as  a  target  of  SIM2s  repression.  Prolonged  hypoxia  induces  cell  death  via  an
autophagic pathway involving the hypoxia-inducible factor 1 (HIF1)-mediated upregula‐
tion of BNIP3 [30,111]. Deregulation of both SIM2s and BNIP3 were associated with poor
prognostic  outcomes [112].  Decreased BNIP3 levels  and poor prognosis  clearly correlate
with elevated SIM2s expression in pancreatic cancer. The loss of BNIP3, either by hyperme‐
thylation or by transcriptional repression, was correlated with inhibition of cell death [113,
114],  whereas  upregulation  of  BNIP3  sensitized  pancreatic  carcinoma  cells  to  hypoxia-
induced  cell  death  [115].  SIM2s  expression,  concomitant  with  its  repression  of  BNIP3,
enhanced  tumor  cell  survival  under  prolonged  hypoxic  conditions.  Recent  data  linked
increased SIM2s expression with enhanced cell survival during hypoxia-stress concomitant‐
ly  with BNIP3 repression and the attenuation of  hypoxia-induced autophagic  processes.
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Thus, inhibition of autophagic cell death by BNIP3 repression enhances tumor cell survival
under prolonged hypoxic conditions [115].
Decreased autophagy in some cancer cells has been related to malignant stages of the disease.
Cancer cells in general tend to undergo less autophagy than their normal counterparts
supporting the contention that defective autophagic cell death plays a role in tumor progres‐
sion. Studies of carcinogen-induced pancreatic cancer in animal models have shown that
pancreatic adenocarcinoma cells have lower autophagic capacity than premalignant cells [116].
The WIPI protein family, which includes ATG18, the WIPI-1 homolog in S. cerevisiae, was
genetically identified as a gene contributing to autophagy [116]. Human WIPI-1a is a member
of a highly conserved WD-repeats protein family. hWIPI-1 is linked to starvation-induced
autophagy in the mammalian system. Amino acid deprivation triggered an accumulation of
endogenous hWIPI-1 protein to large vesicular and cup-shaped structures where it colocalizes
with LC3. Starvation-induced hWIPI-1 formation was blocked by wortmannin, a principal
inhibitor of PI-3 kinase-induced autophagosome formation [117]. Interestingly, WIPI proteins
are linked pathologically to cellular transformation because all human WIPI genes are
reportedly expressed aberrantly in a variety of matched human cancer samples. Strikingly,
hWIPI-2 and hWIPI-4 mRNA expression is substantially decreased in 70% of matched kidney
(10 patients) and 100% of pancreatic (seven patients) tumor samples. The majority of these
samples were derived from advanced-stage tumors such as pancreatic adenocarcinomas stages
I–IV. Hence, cancer-associated downregulation of hWIPI-2 and hWIPI-4 supports the possi‐
bility that decreased autophagic activity is necessary for the malignant stages of pancreatic
cancer.
5. Perspectives
There is ample evidence supporting an active role for autophagy in cell physiology and disease.
During the last decade, autophagy has turned from a morphological finding to a cellular
process involving a membrane transport system and complex molecular machinery. More‐
over, since the discovery of ATG genes, there have been many studies on the physiological
and pathological roles of autophagy in a variety of autophagy knockout models. However,
direct evidence of the connections between ATG gene dysfunction and human diseases has
emerged only recently [56]. Here we have overviewed the physiological bases and molecular
mechanisms of the autophagic process. We have introduced the reader to a novel autophagy-
related transmembrane protein – VMP1 – whose expression triggers autophagy and its role in
the cell response to disease. Elucidation of the specific extracellular and intracellular conditions
that stimulate autophagy and the linkage of these conditions to either cell survival or cell injury
and death in different cell types and during different pathological processes is a rapidly
evolving and fruitful field of research. The development of therapies to take advantage of the
potential cytoprotective effect of autophagy in several pathologies such as cancer or neurode‐
generative diseases is a potentially promising avenue of investigation.
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